GGA to GAA mutations in the 12th codon of the Hras gene are frequently observed in rat mammary tumors induced by N-nitroso-N-methylurea (NMU). We developed an assay to measure point mutations present in tissues at a frequency of 10-5 and have now applied this assay to measure the specific G to A transition of the Hras gene in rat mammary epithelium. We rind that (l) 70% of untreated rats contain detectable levels of Hras mutants; ii) these mutants are dustered within the gland as sectors in a manner consistent with their origin as a mutation arising during early organ development; and (Mi) treatment with a carcinogenic dose of NMU did not result in a sigicant increase in the number of such mutants, the fraction of organ sectors with mutant cells, or the fraction of animals containing detectable levels of ras mutants. We conclude that the NMU-induced mammary tumors carrying the G to A transition at the 12th codon of the Hras gene arose from preexisting ras mutants and that an independent effect of NMU was directly or indirectly responsible for tumor formation. However, such data are also consistent with an alternative hypothesis. The mutation observed in tumors could have existed before chemical exposure. Such exposure could induce unobserved complementary mutations or physiological effects within the Hras mutants that result in tumor formation. Consistent with this possibility is the observation that while the total number of mammary tumors induced per animal increases as a function of NMU dose, the number of tumors harboring the specific Hras gene mutation reaches a stable maximum of -0.7 per animal (8). It has also been noted that the presence of G to A transitions in ras genes among NMU-or ionizing radiation-induced mouse lymphomas corresponded with the genetic background of the mice rather than the mutational specificity of these inducing agents (9, 10).
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To determine whether chemicals cause tumors by mutating cellular oncogenes, Zarbl et al. (1) characterized and compared the type of oncomutations found in N-nitroso-Nmethylurea (NMU)-and 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumors to the knownt (or suspected*) mutational specificity of the inducing carcinogens. A specific G to A transition in the Hras gene was found to be reproducibly associated with NMU-induced rat mammary tumors. This mutation was absent in DMBA-induced mammary tumors, some of which harbored an A to T transversion at the 61st codon ofthe Hras gene. Based on the observations that the same type of tumors induced by different chemicals carried different oncomutations, each of which reflected the suspected mutational specificity of the inducing agents, it was hypothesized that the oncomutations found in tumors were directly caused by the inducing chemicals. The findings of Zarbl et al. (1) were corroborated by Quintanilla et al. (5) , who reported a specific A to T transversion in the Hras gene among DMBA-induced mouse skin tumors. Studies of this type (6) have provided a putative mechanistic link between environmental exposure and cancer risk and have had an impact on regulatory policy formulation (7) .
However, such data are also consistent with an alternative hypothesis. The mutation observed in tumors could have existed before chemical exposure. Such exposure could induce unobserved complementary mutations or physiological effects within the Hras mutants that result in tumor formation. Consistent with this possibility is the observation that while the total number of mammary tumors induced per animal increases as a function of NMU dose, the number of tumors harboring the specific Hras gene mutation reaches a stable maximum of -0.7 per animal (8) . It has also been noted that the presence of G to A transitions in ras genes among NMU-or ionizing radiation-induced mouse lymphomas corresponded with the genetic background of the mice rather than the mutational specificity of these inducing agents (9, 10) .
In raising this alternative hypothesis, we do not imply that carcinogens do not cause any of the recurring specific oncomutations observed in tumors. Clearly, the fact that a variety of oncomutations appear in association with a variety of carcinogens argues that some of them are most probably induced by the carcinogens (11) (12) (13) (14) . However, in the case of Hras gene activation in NMU-induced mammary tumors, we believe that no evidence yet exists to differentiate between these two possibilities (i.e., the carcinogen induced the observed oncomutation or it did not). We have therefore applied the mismatch amplification mutation assay (MAMA) (15) glands were divided into five sectors, each contained on average 7 x 106 cells (see Fig. 2A Fig. 1 ) obtained from samples of genomic DNA isolated from 30 sectors isolated from six different rats. Analyses were carried out in duplicate; + denotes those samples with a ras mutant number that was significantly higher (P < 0.05) than the background (control 0; see Materials and Methods). For each positive sample, mutant number was determined by comparing the radioactivity incorporated into the mutant-specific 74-bp band in each sample to that of the quantitative control set (also see Table 1 ). The 128-bp band in each sample represents the control PCR product using primers P1 and P2 (see Fig. 1 ). (C) Alternative pathways of acquiring NMU-induced mammary lesions containing the ras mutation. Tumors arise from a small number of ras mutants directly induced by NMU (pathway 1) or from preexisting ras mutants (pathway 2). growth advantage as a result of the NMU treatment. At 150 days posttreatment and thereafter, a more rapid increase in mutant cell number occurred and coincided with the appearance of macroscopic tumors, most ofwhich (7/12) carried the 12th codon G to A mutation (data not shown). The ras mutant fraction in 220-day-old untreated animals (0.7 x 10-5) was comparable to that of the 50-day-old untreated animals (0.5 x 10-5), indicating that the outgrowth of the ras mutants is a NMU-mediated effect (unpublished data). Among 54 1-g liver tissue samples isolated from 54 animals sacrificed between 1 and 90 days after NMU exposure, no statistically significant positive signal was detected (data not shown).
The fraction of animals with detectable ras mutants in their mammary epithelium was -0.7 (8/11) before NMU treatment and remained unchanged at 0.7 (46/68) through 280 days posttreatment (Fig. 3) . The fraction of ras-positive animals was thus found to be unaffected by the treatment, suggesting that the majority of tumors with Hras mutations arose in animals with preexisting mutations. Fig. 2B ).
tMutant fraction x (7 x 106 cells). (Also see Fig. 2A MAMA of Sectored Mammary Tissue from NMU-Treated Animals. We could not, however, rule out the possibility that NMU directly induced a small number of ras mutants that were not detectable by the MAMA but were the actual tumor precursors. If this were the case, the number ofHras-positive sectors must increase as the newly induced mutants grow to Data shown here include results from five untreated rats shown in Fig. 1 and six additional untreated rats analyzed in Fig. 2B . t, These three points were omitted from the graph due to space constraints. (15) to measure the number of ras mutant alleles in the target mammary epithelium before and after NMU exposure. We found that the specific oncogenic ras mutants existed before NMU treatment and that treatment did not increase the average number of ras mutants (250 mutants per animal), the fraction ofanimals carrying ras mutants (70%o), or the fraction of tissue sectors with detectable levels of ras mutants (25%).
Because our findings are in direct contradiction to the previous observations ofKumar et al. (25) and Lu Our current findings reopen questions regarding the mechanisms of NMU-induced rat mammary tumorigenesis. Since there are only 200-300 ras mutants in the mammary epithelium of a 50-day-old rat, the NMU-mediated effects must occur at a high frequency in order that at least one of these cells may acquire the additional event(s) necessary for carcinogenesis. Since NMU is a potent mutagen (2, 3, 28) , NMU could conceivably have directly mutated other critical target genes that complemented the tumorigenic potential ofthe ras mutation. However, as noted above, a mutant fraction of 1 in 200 or 300 cells is well above that expected for forward mutations in mammalian cells (2, 3, 28) . The targets of NMU-induced mutagenesis might conceivably be a large set §The number of susceptible epithelial cells in the mammary tissue of a 2-day-old rat was estimated based on the number of target cells at 14 days of age (25) and the observation that both the weight and the surface area of mammary glands increased at a rate comparable to the total body weight and surface area during the first 3 weeks oflife (24) . It was also assumed that the number of cells in an organ is directly proportional to the weight of the organ. The average body weight of a rat at 1, 10, 15, and 20 days of age was 6, 21, 32, and 44 g, respectively (24) . Using a linear regression analysis, the average weights at 2 and 14 days of age were estimated to be 7 and 30 g, respectively. Since (29) . Alternatively, the tumorigenic effects of NMU on the ras mutants may be mediated via nonmutagenic mechanisms. Although the halflife of NMU in vivo is <30 min, the NMU-induced methylation and carbamoylation of cellular macromolecules can persist for days (30, 31) and mediate a number of other biological effects including (i) inhibition of critical cellular enzymatic activities such as DNA repair enzymes (32) and DNA polymerases (33) , (ii) heritable hypomethylation of daughter cell DNA (34) , and (iii) increased cell proliferation due to cytotoxicity of NMU (28) . Given that a mutant Hras allele expressed at normal levels is not transforming (35) , NMU-mediated effects leading to overexpression of the mutated Hras genes are likely mechanisms for NMU-induced carcinogenesis in this tumor model.
The detection of the G to A transition at the 12th codon of the Hras gene in the mammary epithelium of 50-day-old untreated rats directly demonstrates that oncogenic mutations observed in chemically induced tumors arose as background mutations. This result underscores the importance of endogenous mutagens and/or spontaneous mutations in the etiology of human cancer (36, 37) . G to A transitions represent one of the most frequently observed spontaneous mutations (38) , which may arise as a result of cytosine deamination (39) or from exposure to endogenously produced methylating agents such as nitrosamines (40) . If such mutations occur early during development, they could give rise to colonies of cells carrying the activated oncogene (41). Ifthese mutant cells have an increased probability of acquiring a cancer phenotype, then tumors carrying this particular mutation would be observed most frequently.
The type of Hras mutation detected in a small fraction of DMBA-induced mammary tumors was not the same as in NMU-induced tumors (1) . It is thus likely that in DMBAinduced carcinogenesis, the Hras gene is a critical target for mutation by DMBA. The development of a MAMA, which measures this specific 61st codon mutation in the Hras gene, should make it feasible to address this question.
Readers should note that our approach-direct measurement of mutants in untreated tissues-will not be applicable if the number of preexisting oncomutants is below the limit of detection of the method used. For instance, if there had been only one or two cells in the preexisting Hras mutant sectors, we could not have detected them with MAMA and could not have drawn our present conclusions.
In conclusion, we have demonstrated that NMU does not induce the 12th codon GGA to GAA transition in the Hras gene in NMU-induced mammary tumors. This current finding is also in agreement with Mironov et al. (42) , who have recently reported the absence of a mutagenic 06-methylguanosine adduct at the 12th codon of the Hras gene in the rat genomic DNA treated with NMU in vitro. Our observations, however, should not be interpreted to mean that there is no association between oncomutations and carcinogen in other specific cases. The current findings do not contest the importance of Hras gene mutations in tumorigenesis or the importance of chemicals in the etiology of animal and human cancers. However, they clearly illustrate the pitfalls associated with attempts to establish etiology by comparing the types of oncogene mutations seen in tumors with the mutagenic specificity of the suspected carcinogen measured in other cells and DNA sequences.
